Literature DB >> 29207239

The Human Microbiota, Infectious Disease, and Global Health: Challenges and Opportunities.

Abraham J Waldman1, Emily P Balskus1.   

Abstract

Despite significant advances in treating infectious diseases worldwide, morbidity and mortality associated with pathogen infection remains extraordinarily high and represents a critical scientific and global health challenge. Current strategies to combat these infectious agents include a combination of vaccines, small molecule drugs, increased hygiene standards, and disease-specific interventions. While these approaches have helped to drastically reduce the incidence and number of deaths associated with infection, continued investment in current strategies and the development of novel therapeutic approaches will be required to address these global health threats. Recently, human- and vector-associated microbiotas, the assemblages of microorganisms living on and within their hosts, have emerged as a potentially important factor mediating both infection risk and disease progression. These complex microbial communities are involved in intricate and dynamic interactions with both pathogens as well as the innate and adaptive immune systems of their hosts. Here, we discuss recent findings that have illuminated the importance of resident microbiotas in infectious disease, emphasizing opportunities for novel therapeutic intervention and future challenges for the field. Our discussion will focus on four major global health threats: tuberculosis, malaria, HIV, and enteric/diarrheal diseases. We hope this Perspective will highlight the many opportunities for chemists and chemical biologists in this field as well as inspire efforts to elucidate the mechanisms underlying established disease correlations, identify novel microbiota-based risk factors, and develop new therapeutic interventions.

Entities:  

Keywords:  HIV; enteric disease; global health; infectious disease; malaria; microbiota; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 29207239     DOI: 10.1021/acsinfecdis.7b00232

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  9 in total

1.  Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection.

Authors:  Vikram Mehraj; Rayoun Ramendra; Stéphane Isnard; Franck P Dupuy; Rosalie Ponte; Jun Chen; Ido Kema; Mohammad-Ali Jenabian; Cecilia T Costinuik; Bertrand Lebouché; Réjean Thomas; Pierre Coté; Roger Leblanc; Jean-Guy Baril; Madeleine Durand; Carl Chartrand-Lefebvre; Cécile Tremblay; Petronela Ancuta; Nicole F Bernard; Donald C Sheppard; Jean-Pierre Routy
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

2.  A Mismatch-tolerant RT-LAMP Method for Molecular Diagnosis of Highly Variable Viruses.

Authors:  Yingxue Li; Yi Zhou; Yingying Ma; Rong Xu; Xia Jin; Chiyu Zhang
Journal:  Bio Protoc       Date:  2019-11-05

Review 3.  Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

Authors:  Francesca Rossi; Chiara Tortora; Maura Argenziano; Alessandra Di Paola; Francesca Punzo
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 4.  Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation.

Authors:  Rayoun Ramendra; Stéphane Isnard; Vikram Mehraj; Jun Chen; Yonglong Zhang; Malcolm Finkelman; Jean-Pierre Routy
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

Review 5.  Examining the Complex Relationship Between Tuberculosis and Other Infectious Diseases in Children.

Authors:  Elizabeth Whittaker; Elisa López-Varela; Claire Broderick; James A Seddon
Journal:  Front Pediatr       Date:  2019-06-25       Impact factor: 3.418

Review 6.  Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings.

Authors:  Suprabhat Mukherjee; Nikhilesh Joardar; Subhasree Sengupta; Santi P Sinha Babu
Journal:  J Nutr Biochem       Date:  2018-08-16       Impact factor: 6.048

7.  A murine model of tuberculosis/type 2 diabetes comorbidity for investigating the microbiome, metabolome and associated immune parameters.

Authors:  Harindra D Sathkumara; Janet L Eaton; Matt A Field; Brenda L Govan; Natkunam Ketheesan; Andreas Kupz
Journal:  Animal Model Exp Med       Date:  2021-03-23

Review 8.  Lights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients.

Authors:  Pablo Villoslada-Blanco; Patricia Pérez-Matute; José A Oteo
Journal:  Int J Environ Res Public Health       Date:  2021-06-25       Impact factor: 3.390

9.  A biofoundry workflow for the identification of genetic determinants of microbial growth inhibition.

Authors:  Alaster D Moffat; Adam Elliston; Nicola J Patron; Andrew W Truman; Jose A Carrasco Lopez
Journal:  Synth Biol (Oxf)       Date:  2021-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.